Monosaccharide substrate replacement therapy for an ultra-rare congenital disorder of glycosylation
CERC-803 is an ultra-pure, oral formulation of L-fucose currently in development for the treatment of Leukocyte Adhesion Deficiency Type II (LADII), also known as SLC35C1-CDG.
Currently there is no approved product for the treatment CDG-IIc.
CDG-IIc is caused by loss of function mutations in the SLC35C1 gene encoding a GDP-fucose transporter found in the Golgi apparatus, where it acts as the donor substrate for protein fucosylation.
We believe that substrate replacement with CERC-803 in patients with CDG-IIc is expected to reverse the hypofucosylation defects found in this patient population.
View our posters and publications for CERC-803
Learn more about the CNS disorders we’re targeting, as well as contact information
2019 Annual Meeting of Stockholders
Rockville, Maryland | Aug 7, 2019 • 8:30am EDT